Lipid checks boost statin adherence among patients with ASCVD

  • Jia X & al.
  • Am J Med
  • 16 May 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Lipid panels at statin initiation and dose change in patients with atherosclerotic cardiovascular disease (ASCVD) boost adherence.
  • A higher number of lipid panels is tied to higher adherence. 

Why this matters

  • Cholesterol management guidelines recommend routine lipid panels to track drug effectiveness and adherence.

Key results

  • Patients had an average of 1.54 panels.
  • With ≥1 lipid panel, 66.0% had ≥80% of days covered vs 61.2% with no panel conducted (P<.0001>
  • Association between proportion of days covered and number of panels was significant (P<.001> OR, 1.009 (95% CI, 1.004-1.014).
  • With statin initiation, 68.0% who had a panel within 4-12 weeks hit ≥80% of days covered vs 59.3% of those who did not (P<.0001>
  • For new users, the association was significant (P<.001 or ci>
  • Being treated by a primary care clinician was linked to decreased adherence. 

Study design

  • 813,887 US Veterans Affairs (VA) patients with ASCVD; 52,583 were new statin users.
  • Funding: Department of Veterans Affairs Health Services, others.

Limitations

  • Patients could have had panels outside the VA.
  • Adherence based on refill data.